Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 13/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3131919 | 0.86 | LCK (0.60) | LCKCA12CA1CA9NLRP3 | |
| SCHEMBL20865564 | 0.86 | LCK (0.50) | LCKCA12CA1CA9ATR | |
| SCHEMBL17528556 | 0.84 | LCK (0.49) | LCKCA12CA1CA9ATR | |
| SCHEMBL25243093 | 0.83 | LCK (0.62) | LCKCA12CA1CA9 | |
| SCHEMBL17528554 | 0.81 | LCK (0.50) | LCKCA12CA1CA9ATR | |
| SCHEMBL30830459 | 0.81 | LCK (0.47) | LCKCA12CA1CA9ATR | |
| SCHEMBL557858 | 0.79 | SMN1; SMN2 (0.46) | CA12CA1CA9 | |
| SCHEMBL24233914 | 0.79 | LCK (0.46) | LCKCA12CA1CA9ATR | |
| SCHEMBL1689760 | 0.79 | CA12 (0.43) | CA12CA1CA9ATR | |
| SCHEMBL24574915 | 0.79 | LCK (0.60) | LCKATRNLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4582428-A1 | PYRAZOLOPYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 2025-07-09 | — | — | EP | disclosed |
| US-20250114361-A1 | PYRAZOLOPYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2025-04-10 | — | — | US | disclosed |
| CN-119790055-A | Pyrazolopyrimidine compound and medical use thereof | 日本烟草产业株式会社 | 2025-04-08 | — | — | CN | disclosed |
| WO-2024048519-A1 | PYRAZOLOPYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | 日本たばこ産業株式会社 | 2024-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114361-A1 | PYRAZOLOPYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | NLRP3, NLRP1, PYCARD | LCK 1258/4885CA12 4579/4885CA1 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.